NIH Weekly Funding Opportunities and Policy Notices

Wednesday, January 25, 2017 - 9:58am
Funding Opportunity PA-17-134 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This FOA is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes. The R03 Small Research Grant Program supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding. This program supports different types of projects including (but not limited to) pilot or feasibility studies; secondary analysis of existing data; small, self-contained research projects; and development of research methodology.
Wednesday, January 25, 2017 - 9:58am
Funding Opportunity PA-17-132 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This FOA is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes.
Wednesday, January 25, 2017 - 9:58am
Funding Opportunity PA-17-135 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This FOA is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes.
Wednesday, January 25, 2017 - 1:43am
Notice NOT-MH-17-009 from the NIH Guide for Grants and Contracts
Wednesday, January 25, 2017 - 1:39am
Notice NOT-CA-17-021 from the NIH Guide for Grants and Contracts
Tuesday, January 24, 2017 - 11:02pm
Notice NOT-CA-17-020 from the NIH Guide for Grants and Contracts
Tuesday, January 24, 2017 - 9:44am
Funding Opportunity PA-17-131 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK with the STTR program. STTR Phase I projects under this FOA support preliminary steps in the process for lead optimization or preclinical development of therapeutics. STTR Phase II supports lead optimization and preclinical development of lead candidates, and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a STTR Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go / No Go decision points.
Tuesday, January 24, 2017 - 9:44am
Funding Opportunity PA-17-130 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK with the SBIR program. SBIR Phase I projects under this FOA supportpreliminary steps in the process for lead optimization or preclinical development of therapeutics. SBIR Phase II supports lead optimization and preclinical development of lead candidates, and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a SBIR Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go / No Go decision points.
Monday, January 23, 2017 - 8:48am
Notice NOT-OD-17-040 from the NIH Guide for Grants and Contracts
Monday, January 23, 2017 - 12:55am
Notice NOT-TW-17-003 from the NIH Guide for Grants and Contracts
Sunday, January 22, 2017 - 11:56pm
Notice NOT-CA-17-022 from the NIH Guide for Grants and Contracts
Thursday, January 19, 2017 - 9:50am
Funding Opportunity PAR-17-129 from the NIH Guide for Grants and Contracts. This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption.
Thursday, January 19, 2017 - 9:50am
Funding Opportunity PAR-17-128 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials.
Thursday, January 19, 2017 - 7:52am
Funding Opportunity RFA-NS-17-020 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose outstanding records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II) This greater funding stability will provide investigators with increased freedom and flexibility which may allow them to be more adventurous in their research, to take greater risks, to embark upon research that breaks new ground, to undertake research projects that require a longer timeframe, and/or to extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program.
Wednesday, January 18, 2017 - 11:55pm
Notice NOT-OD-17-039 from the NIH Guide for Grants and Contracts
Wednesday, January 18, 2017 - 11:40pm
Notice NOT-OD-17-038 from the NIH Guide for Grants and Contracts
Wednesday, January 18, 2017 - 11:29pm
Notice NOT-OD-17-037 from the NIH Guide for Grants and Contracts
Wednesday, January 18, 2017 - 8:01am
Funding Opportunity PAR-17-127 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite pilot/feasibility projects for: 1) descriptive studies to identify putative juvenile protective factors, 2) experimental studies to test hypotheses about their effects on aging and 3) translational studies to characterize potential beneficial and adverse effects of maintaining or modulating the level of juvenile protective factors in adult life. Juvenile protective factors (JPFs), intrinsic to an immature organism, help to maintain or enhance certain physiological functions across all or some stages of postnatal development (i.e., segment of the life span between birth and sexual maturity), but diminish or disappear as the organism transitions from one maturational stage to the next. The loss or diminution of JPFs after a given stage of postnatal development or at time of sexual maturity may contribute to the onset of deleterious aging changes (e.g., compromised stem cell function and reparative capacity) across adulthood. This FOA is uniquely focused on animal and clinical studies which involve comparisons between juvenile versus adult states or between stages of postnatal development to identify putative JPFs and their effects on aging. Pilot studies which involve comparisons between young and old adults will not be supported by this FOA.
Wednesday, January 18, 2017 - 8:01am
Funding Opportunity PAR-17-126 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to invite: 1) descriptive studies to identify putative juvenile protective factors, 2) experimental studies to test hypotheses about their effects on aging and 3) translational studies to characterize potential beneficial and adverse effects of maintaining or modulating the level of juvenile protective factors in adult life. Juvenile protective factors (JPFs), intrinsic to an immature organism, help to maintain or enhance certain physiological functions across all or some stages of postnatal development (i.e., segment of the life span between birth and sexual maturity), but diminish or disappear as the organism transitions from one maturational stage to the next. The loss or diminution of JPFs after a given stage of postnatal development or at time of sexual maturity may contribute to the onset of deleterious aging changes (e.g., compromised stem cell function and reparative capacity) across adulthood. This FOA is uniquely focused on animal and clinical studies which involve comparisons between juvenile versus adult states or between stages of postnatal development to identify putative JPFs and their effects on aging. Studies which involve comparisons between young and old adults will not be supported by this FOA.

Pages